Kornimate/medical-research-clean huggingface dataset:
the rule of bupivacaine hydrochloride in skin graft donor site

Conditions: Skin Graft Complications; Pain Management

Summary: split thickness skin graft is frequently utilized for reconstructing skin loss of various causes. unfortunately, the donor site of the stsg has an unavoidable, annoying post-operative pain

the primary objective of this study was to compare the efficacy of bupivacaine hydrochloride-soaked dressing versus bupivacaine hcl subcutaneous infiltration for postoperative donor site pain control for patients undergoing stsg procedures. the patients were divided in 3 equal groups, investigated soaked dressing vs subcutaneous infiltration vs conventional dressing .

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status classification i-ii * scheduled for stsg harvested from a single thigh donor site to reconstruct skin loss post burn or trauma exclusion criteria: * uncooperative * refusing patient, * under immunosuppressive treatment * diabetics * lower-limb neuropathy * under corticosteroids treatment * allergy to the study drug, * stsg procedures performed under spinal anesthesia * pregnancy * had a history of opioid abuse

Keywords: bupivacaine skin graft pain donor site local anesthesia
comparing satisfaction with a participatory driven web-application and a standard website

Conditions: Low Back Pain

Summary: this project studies the effects of involving patients in the development of a web-application.

the point-prevalence of low back pain (lbp) has been estimated to 9.4 % and lbp is in many countries the most frequent reason to consult a general practitioner. however, general practitioners are under pressure with increasing workloads. the increasing number of patients and the typical 10-15 minutes of available time for each patient are challenging the provision of sufficient information and advice. according to international guidelines information and advice are recommended for every patient with lbp, therefore, new methods to support general practitioners (gps) are very much needed. online technologies give new opportunities to extend the treatment. furthermore, involving patients with lbp in the development of online information material may produce more user friendly content and design and thereby increasing patients' acceptance and usage. thus, optimizing clinical outcome. this project will study patients' satisfaction and clinical outcomes of a web-application for patients with lbp consulted in general practice compared to best existing technology (the patient handbook).

Eligibility criteria:
inclusion criteria: * contacting general practice with low back pain exclusion criteria: * spinal stenosis * spine fractures * cauda equina syndrome * spinal malignancy * osteoporosis * spondyloarthritis * without danish reading skills * without internet access * pregnant women

Keywords: low back pain
the impact of anti- asthmatic medications on salivary ph and dental caries pattern in a group of egyptian children with bronchial asthma

Conditions: pH

Summary: the impact of anti- asthmatic medications on salivary ph and dental caries pattern in a group of egyptian children with bronchial asthma.

due to lack of published studies about the impact of anti-asthmatic medications on salivary ph and dental caries pattern among the egyptian children diagnosed with bronchial asthma, this study will be conducted to cover this point.

Eligibility criteria:
inclusion criteria: * - children aged 6-12 years old diagnosed with bronchial asthma (mixed dentition stage). * control group : a matched group aged 6-12 years old * patients taking regular medications for the treatment of bronchial asthma at least for 1 year back * both male and female patients will be included. exclusion criteria: * no other systemic diseases.
telemonitoring in pulmonary rehabilitation: feasibility and acceptability of a remote pulse oxymetry system.

Conditions: Chronic Obstructive Pulmonary Disease; Pulmonary Rehabilitation; Telemedicine

Summary: pulmonary rehabilitation effectively improves outcomes in patients with chronic respiratory disease, however there is a lack of pulmonary rehabilitation centers. telehealth technology is one solution to deliver supervised home-based rehabilitation (tele-rehabilitation). however, the feasibility and the acceptability of using telehealth technology to deliver tele-rehabilitation has not been assessed in a large scale multicenter study. therefore, the aim of this study is to assess the feasibility and the acceptability of telemonitoring system during pulmonary rehabilitation in patients with chronic respiratory disease.


Eligibility criteria:
inclusion criteria: * age \> 18 years ; * referred for pulmonary rehabilitation (every chronic respiratory disease accepted). exclusion criteria: * pregnant woman or likely to be ; * patient under guardianship ; * neuropathic disorder ; * contraindication to cardiopulmonary exercise testing or pulmonary rehabilitation.
safety and efficacy of daily use of micamlo® combination tablets ap in patients with hypertension

Conditions: Hypertension

Summary: investigation of safety and efficacy of daily use of micamlo combination tablets ap in patients with hypertension


Eligibility criteria:
inclusion criteria: - male and female patients with hypertension who did not receive of micamlo combination tablets ap before the start of the study exclusion criteria: * patients with a history of hypersensitivity to any ingredient of micamlo combination tablets ap and dihydropyridine derivatives * pregnant woman or possibly pregnant woman * patients with extremely poor bile secretion or patients with serious hepatic disorder
local anesthetics after total knee arthroplasty

Conditions: Postoperative Pain

Summary: the aim of this randomized, double-blind and placebo-controlled study is to evaluate the specific role of injection of local anesthetic into the intra- vs. extraarticular tissues after toal knee arthroplasty.


Eligibility criteria:
inclusion criteria: * able to give informed oral and written consent to participate * able to speak danish exclusion criteria: * treatment with opioids * body mass index \> 40

Keywords: pain local infiltration analgesia
personality style and self compassion in postpartum depression: an online prevention study

Conditions: Postpartum Depression

Summary: the primary aim of this study is to assess the relationship between personality style, self-compassion and depression during pregnancy, to identify psychological risk factors, particularly personality styles, that may contribute to the onset of ppd. additionally, the study will provide support for the effectiveness of internet-based compassionate-mind training (icmt) as a prevention intervention for postpartum depression (ppd) for women in the 2nd and 3rd trimester of pregnancy. the study will also assess differences along personality predictors and depression severity as they relate to intervention outcomes (i.e. depression in postpartum and self-compassion) and engagement. the researchers hypothesize that women both at high and low risk for ppd will receive benefits from the intervention, however, those who endorse more maladaptive personality traits will likely engage and benefit less than those who do not endorse these traits.


Eligibility criteria:
inclusion criteria: * pregnant women in the second and third trimester exclusion criteria: * under 18 years of age * males * women who are not pregnant * pregnant women in the first trimester of pregnancy or over 36 weeks pregnant * women who likely meet criteria for a major depressive episode * women currently in in-person psychological tx
international rare brain tumor registry

Conditions: Astroblastoma; BCOR ITD Sarcoma; CNS Sarcoma; Unclassified Tumor, Malignant

Summary: the objective of the international rare brain tumor registry (irbtr) is to better understand rare brain tumors through the collection of biospecimens and matched clinical data of children, adolescents, and young adult patients diagnosed with rare brain tumors.

the international rare brain tumor registry (irbtr) is a prospective observational study that will collect tumor samples and matched clinical and radiological data to better understand the outcomes of patients with rare brain tumors in particular: cns sarcoma, bcor, mn-1 altered tumors, and other unclassified rare brain tumors. data collected include demographics, disease characteristics, treatment information, radiological imaging, and biospecimen collection if available ( tumor tissues patients will be followed longitudinally to obtain outcome data. data collection will continue for approximately 10 years.

Eligibility criteria:
inclusion criteria: * patients with a known or suspected cns sarcoma. * patients with a known or suspected bcor-altered brain tumor * patients with a known or suspected astroblastoma/nm-1 altered brain tumor * patients with known or suspected histologically ambiguous/unclassifiable brain tumor * patients with a known or suspected rare brain tumor. * signed informed consent by patient/ parent or guardian (assent where applicable) to participate in the study. exclusion criteria: * the patient has an extra-cns primary tumor. * the patient is older than 46 years of age at diagnosis. * the patient or family is not willing to participate or does not sign informed consent.

Keywords: rare brain tumor pediatric brain tumor registry unclassifiable tumor pediatric neuro-oncology rare disease
an efficacy and safety study of galantamine for the treatment of patients with alzheimer's disease.

Conditions: Alzheimer Disease

Summary: the purpose of this study is to evaluate the efficacy and safety of two fixed doses (16mg/day and 24mg/day) of galantamine (a drug for treating dementia) versus placebo for the treatment of patients with alzheimer's disease, and to investigate the dose-response.

this is a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two fixed doses of galantamine (16 and 24 milligrams per day \[mg/day\]) in patients with alzheimer's disease, and to investigate the dose-response. the study consists of a 4-week screening period during which all patients will receive placebo, and a 22-week double-blind treatment period during which patients will receive placebo, galantamine 16 mg/day, or galantamine 24 mg/day. for patients receiving galantamine treatment, the starting dose is 8 mg/day and increases at 4-week intervals in increments of 8 mg/day. the primary measures of effectiveness are the change from baseline to the end of the study (week 22) in the alzheimer's disease assessment scale - japan cognitive subscale (adas-j cog) and the clinician's interview-based impression of change plus - japan (cibic plus-j). safety assessments include the incidence of adverse events, clinical laboratory tests, vital signs, electrocardiograms (ecgs), and physical examination findings. the study hypothesis is that galantamine will be more effective in the treatment of alzheimer's disease than placebo. study drug taken orally twice a day. 4-week screening period: all patients receive placebo. 22-week treatment period: patients receive placebo, galantamine 16 mg/day, or 24 mg/day. for galantamine treatment, the starting dose is 8 mg/day and increases at 4-week intervals in increments of 8 mg/day.

Eligibility criteria:
inclusion criteria: * outpatients with a diagnosis of alzheimer's disease according to the national institute of neurological and communicative disorders and the alzheimer's disease and related disorders association (nincds-adrda) criteria * having a mini-mental status examination (mmse) score of 10 - 22 inclusive * having an alzheimer's disease assessment scale - japan cognitive subscale (adas-j cog) score of at least 18 * exhibiting an onset and progression of cognitive dysfunction during at least 6 months prior to the screening period exclusion criteria: * patients with neurodegenerative diseases other than alzheimer's disease, such as lewy bodies disease, (dementia due to tiny round structures made of proteins that develop within nerve cells in the brain), parkinsonism, etc * patients with cognitive dysfunction due to cerebral damage resulting from a lack of oxygen, a brain injury, etc * patients with multi-infarct dementia (brought on by a series of strokes) or active cerebrovascular disease * patients with clinically significant cardiovascular disease * patients currently taking drugs such as a cholinesterase inhibitors, which improve cerebral circulation/metabolism

Keywords: alzheimer's disease cognitive dysfunction
nerve access tool study

Conditions: Cystocele

Summary: the purpose of this study is to assess the ability of the nerve access tool to facilitate nerve stimulation lead placement.


Eligibility criteria:
inclusion criteria: * subject is equal to or greater than 18 years of age * subject has a diagnosis of cystocele with planned surgical repair * subject has no known deficit of the nerve * subject is willing and able to provide written informed consent and hipaa authorization to participate by signing the informed consent/health insurance portability and accountability act form after a full explanation of the nature and purpose of this study * subject is willing and able to comply with the study protocol exclusion criteria: * subject has known neurological abnormalities of the nerve * subject has a known allergy to the tool or neurostimulation lead components * subject is pregnant or lactating

Keywords: the focus of the study is to assess the ability of the nerve access tool to facilitate nerve lead placement
variations of cognitive behavior therapy for social anxiety disorder

Conditions: Social Anxiety Disorder

Summary: the purpose of this study is to compare the efficacy of two variants of cognitive behavioral therapy (cbt) (cognitive therapy (ct) and acceptance and commitment therapy (act)), for the treatment of generalized social anxiety disorder.

we are recruiting a clinical sample of patients who meet diagnostic criteria (per dsm-5) for the generalized subtype of social anxiety disorder. participants are randomly assigned to the two active intervention conditions; no placebo or sham treatments will be employed. assessments take place at baseline, pre-treatment, mid-treatment, post-treatment, and at 3- and 12-months follow-up; participants also complete a brief weekly assessment of functioning. treatment is administered individually by trained graduate students in clinical psychology, directly trained and supervised by the pi and co-pi. participants receive 12 weekly 1-hour long sessions. the study design is a 2 (treatment condition) by 5 (assessment occasion) mixed factorial design.

Eligibility criteria:
inclusion criteria: * clinically diagnosable social anxiety disorder (generalized subtype per dsm-iv-tr criteria) * aged 18-65 * working fluency in english * residence in the greater philadelphia area. exclusion criteria: * pervasive developmental disability * acute suicide potential * inability to travel to the treatment site * schizophrenia or other psychotic disorder * current substance dependence * comorbid diagnoses of major depressive or other mood or anxiety disorders are acceptable only if clearly secondary to the diagnosis of social anxiety disorder.

Keywords: social anxiety treatment cognitive behavioral therapy acceptance and commitment therapy cognitive therapy
vpd-737 for treatment of chronic pruritus

Conditions: Chronic Pruritus

Summary: a study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments

the sensation of itch is transmitted to the brain through the nervous system several chemicals are involved in transmitting this signal this trial of vpd 737 is intended to treat this condition by blocking one of the chemicals involved in the transmission of the itch signal this is an oral drug administered once daily it has been used in other trials and has shown to be safe at the doses used in this trial the trial will involve once daily pills for 6 weeks. subject will be asked to fill out questionnaires both electronically and on paper during the study period patients will also be monitored for safety and will have blood taken for testing and several points during the trial overall participation will last about 12 weeks

Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic pruritus and unresponsive to current therapies exclusion criteria: * have chronic liver or renal disease
actavisc and actavisc mx intra-articular injection for pain associated with osteoarthritis in the knee

Conditions: Osteoarthritis

Summary: to evaluate the safety and performance of actavisc™ intra-articular injection (actavisc) and actavisc mx, for management of pain associated with osteoarthritis in the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics


Eligibility criteria:
inclusion criteria: * osteoarthritis (oa) grade 2 or 3. * symptoms in the treatment knee for at least 12 months. * fully ambulatory patient. exclusion criteria: * secondary oa resulting from rheumatoid arthritis, chondrocalcinosis, osteonecrosis, chronic fibromyalgia or other autoimmune disease. * generalized symptomatic oa in lower extremity joints other than the knees, inflammatory joint disease, bursitis, oa in the hips, or other condition that may interfere with study assessments.
comparison of class ii and class iii hysterectomy in early stage cervical cancer cervical cancer

Conditions: Cervical Cancer

Summary: based on the value-based medicine, a randomized clinical trial was conducted to compare the role of class ii and class iii hysterectomy in patients with low risk early staged cervical cancer (defined as tumor lesions less than 2cm with less than 50% stromal invasion).

this is a 1:1 multi-center randomized trial with class ii hysterectomy plus node dissection as the experimental arm, and class iii hysterectomy plus pelvic node dissection as the control arm. primary endpoints are: (1). 3-year diseases-free survival (dfs) rate; (2) the rates of treatment-related toxicity; (3) post-operation qol (including sexual function) and (4) treatment costs. secondary endpoints are：(1) the rates of pelvic and/or extra-pelvic relapse; (2) overall survival(os) rate; (3) the numbers of retroperitoneal node dissection, and (4) the rates of parametrial, margins and pelvic/para-aortic nodes involvement.

Eligibility criteria:
inclusion criteria: 1. stage ia2 and small ib1 \<2 cm 2. less than 50% stromal invasion based on mri or 10mm stromal invasion based on the pathology measurement of the leep/cone specimen 3. squamous or adenocarcinoma or adenosquamous 4. grade 1, 2 and 3 5. lymph-vascular space invasion (lvsi): presence or absence 6. diagnosis confirmed by leep/cone/cervical biopsy 7. pelvic mri in patients with involved cone/leep margins and those who had cervical biopsy only 8. abdomino-pelvic ct scan in patients with negative leep-cone margins 9. no contraindications to surgery 10. no desire to preserve fertility 11. informed consent exclusion criteria: 1. high-risk histology types (clear cell, small cell etc) 2. evidence of lymph node metastasis on preoperative imaging 3. stage 1a1 4. neo-adjuvant chemotherapy 5. pregnancy 6. desire to preserve fertility
efficacy of electrical pudendal nerve stimulation and sacral in treating non-obstructive neurogenic urinary retention

Conditions: Urinary Retention

Summary: to observe the clinical effects and make a comparative study between efficacy of electrical pudendal nerve stimulation (epns) and sacral neuromodulation (snm) , evaluate the advantages of epns in the treatment of neurogenic non-obstructive urinary retention, and provide a new method for the treatment of the disease.


Eligibility criteria:
inclusion criteria: * non-mechanical obstructive urinary retention occurs following relevant neurological system disorders (spinal cord injury, spina bifida，myelitis, cervical/thoracic disk disease, lesion following spinal anesthesia/spine surgery,lumbar/sacral spine intervertebral disc diseases, spinal stenosis, iatrogenic pelvic nerve lesions, sacral agenesis, peripheral neuropathy due to diabetes mellitus). * with normal upper urinary tract function. * other therapies and medications potentially affecting the assessment of this therapy have been discontinued for at least two weeks before the interventional procedure. * patient with good compliance who is capable of cooperating with the follow-up requirements exclusion criteria: * patients with any suprapontine and pontine lesions * pregnant or lactating women * individuals whose symptoms show significant improvement after pharmaceutical and adjunctive therapy * individuals with concurrent acute or chronic prostatitis, prostate cancer, or conditions such as bladder neck stenosis, urethral stricture, or urethral injury * high pathological risk factors (e.g., lymph node metastasis, resection margin involvement, bulky tumors) * individuals with concomitant obstructive urinary retention
efficacy and safety of dual therapy as first-line treatment for hp infection

Conditions: Helicobacter Pylori Infection

Summary: this study aims to evaluate the efficacy of dual therapy compared with bismuth-containing quadruple therapy as first-line treatment for helicobacter pylori eradication, as well as the safety and economic benefits.


Eligibility criteria:
inclusion criteria: 1. having h. pylori related chronic gastritis confirmed by ¹³c-urea breath test, ¹⁴c-urea breath test and/or biopsy； 2. underwent gastroscopy within 1 year before treatment, liver and renal function tests and electrocardiogram within 3 months before treatment； 3. with no historical treatment for helicobacter pylori infection. exclusion criteria: 1. administration of antibiotics, bismuth in 4 weeks prior to inclusion or antacids including h2 receptor antagonist, proton pump inhibitor and potassium-competitive acid blocker in 2 weeks prior to inclusion 2. with previous esophageal or gastric surgery 3. with severe systemic diseases, major organ like heart, lung, brain diseases, liver or kidney insufficiency, malignant tumor or other diseases 4. allergy to any of the study drugs 5. participated in other research within 3 months，cannot express his/her own ideas correctly or cannot cooperate with the researcher

Keywords: dual therapy bismuth-containing quadruple therapy helicobacter pylori